v3.25.2
Significant acquisition of businesses (Details 4)
 6 Months Ended
Jun. 25, 2025
USD ($)
Jun. 24, 2025
USD ($)
Apr. 03, 2025
USD ($)
Jun. 30, 2025
USD ($)
Jul. 11, 2025
USD ($)
May 27, 2025
USD ($)
Regulus Therapeutics Inc.            
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]            
Cash offer per outstanding share for acquisitions applying the optional concentration test           $ 7.00
Contingent value right per share for acquisitions applying the optional concentration test           $ 7.00
Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test $ (800,000,000) $ (700,000,000)        
Number of contingent value per share issued for acquisitions applying the optional concentration test   1        
Liability related to employee share plans for acquisitions applying the optional concentration test         $ 100,000,000  
Contingent value right amount for acquisitions applying the optional concentration test 900,000,000          
Intangible assets other than goodwill for acquisitions applying the optional concentration test 800,000,000          
Anthos Therapeutics Inc.            
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]            
Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test     $ (900,000,000)      
Intangible assets other than goodwill for acquisitions applying the optional concentration test     900,000,000      
Potential milestone maximum payment for acquisitions applying the optional concentration test     2,100,000,000      
Cash and cash equivalents recognised as of acquisition date            
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]            
Cash and cash equivalents in subsidiary or businesses acquired or disposed       $ 70,000,000    
Cash and cash equivalents recognised as of acquisition date | Regulus Therapeutics Inc.            
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]            
Cash and cash equivalents in subsidiary or businesses acquired or disposed $ 23,000,000          
Cash and cash equivalents recognised as of acquisition date | Anthos Therapeutics Inc.            
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]            
Cash and cash equivalents in subsidiary or businesses acquired or disposed     $ 47,000,000